BioCentury
ARTICLE | Company News

Five Prime, bluebird to develop CAR T therapies

May 27, 2015 12:46 AM UTC

Five Prime Therapeutics Inc. (NASDAQ:FPRX) gained $3.78 (19%) to $23.45 in early after-hours trading Tuesday after post-market news that it partnered with bluebird bio Inc. (NASDAQ:BLUE) to develop chimeric antigen receptor (CAR) T cell therapies.

Five Prime will grant bluebird exclusive rights to preclinical-stage human antibodies against an undisclosed target. bluebird will use its lentiviral gene therapy platform and existing CAR T capabilities to develop therapies against the target. ...